Sort   by:  
 Page size 
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42019 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42020 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgG 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42163 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation IgM 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42175 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42145 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training Total Ig 1:200]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42150 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:200]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42179 | biostudies-arrayexpress
ProteomicsBaseline serum anti-glycan antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Validation Total Ig 1:50]
Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. Thi...
ORGANISM(S): Homo sapiens 
2013-04-01 | E-GEOD-42176 | biostudies-arrayexpress
Genomics58C
T1DGC project 1958 British Birth Cohort samples
EGAD00000000030 | EGA
GenomicsT1DGC GWAS 1958 British Birth Cohort controls
T1DGC genome-wide case-control association study for Type 1 Diabetes (T1D) using the 1958 British Birth Cohort as controls. The cases for this study are made available from the NCBI dbGAP.
EGAS00000000038 | EGA
Sort   by:  
 Page size